Emily C. Craver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Emily C. Craver has a total of 117 co-authors. Here are the top co-authors by number of shared publications:
- Abby Hanson
Mayo Clinic, Florida
2 shared publications - Andrey P. Morozov
Department of Radiology, Mayo Clinic, Jacksonville, FL 32224, USA
2 shared publications - Anna Bovill Shapiro
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Jacksonville, USA
2 shared publications - Arvind Balavenkataraman
Department of Critical Care Medicine, Department of Pulmonary and Critical Care, Mayo Clinic in Florida, 4500 San Pablo Rd S, Jacksonville, FL32224
2 shared publications - Aysun Tekin
Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA
2 shared publications - Bhavesh Patel
Department of Critical Care, Mayo Clinic, Phoenix, AZ
2 shared publications
Latest Publications
- Open Access
- 30 April 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Procedural outcomes in patients undergoing non-cardiac surgery with cardiac variant amyloidosis
Amyloidosis is a complex disease with a multitude of sequalae, particularly with the variants that cause cardiac amyloidosis. There is minimal literature o
- 30 April 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessProcedural outcomes in patients undergoing non-cardiac surgery with cardiac variant amyloidosis
Amyloidosis is a complex disease with a multitude of sequalae, particularly with the variants that cause cardiac amyloidosis. There is minimal literature o
- Open Access
- 17 March 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (5) , 108611
Carotid revascularization and hemispheric white matter disease progression
- 17 March 2026
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 35 (5) , 108611
Open AccessCarotid revascularization and hemispheric white matter disease progression
- 1 October 2024
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 117 (10) , 603-608
Racial and Ethnic Disparities in Pediatric Atopic Dermatitis
Objectives: Atopic dermatitis (AD) is one of the most common chronic childhood conditions. Disparities in treatment and access to care can result in poor disease control and decreased quality of life. The aim of this study was to determine whether race and ethnicity affect treatment and healthcare utilization for pediatric atopic dermatitis in central Florida. Methods: This study of 4008...
- 1 October 2024
- Published by Southern Medical Association in Southern Medical Journal
- Vol. 117 (10) , 603-608
Racial and Ethnic Disparities in Pediatric Atopic Dermatitis
Objectives: Atopic dermatitis (AD) is one of the most common chronic childhood conditions. Disparities in treatment and access to care can result in poor disease control and decreased quality of life. The aim of this study was to determine whether race and ethnicity affect treatment and healthcare utilization for pediatric atopic dermatitis in central Florida. Methods: This study of 4008...
- 4 September 2024
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 31 (12) , 1026-1033.e2
Tissue Retrieval of Laparoscopically Excised Adnexal Specimens in Gynecologic Surgery: Posterior Culdotomy Versus Abdominal Extraction
- 4 September 2024
- Published by Elsevier in Journal of Minimally Invasive Gynecology
- Vol. 31 (12) , 1026-1033.e2
Tissue Retrieval of Laparoscopically Excised Adnexal Specimens in Gynecologic Surgery: Posterior Culdotomy Versus Abdominal Extraction
- 12 August 2024
- Published by Springer Nature in Spine Deformity
- Vol. 12 (6) , 1657-1665
Improving prediction of progression of idiopathic scoliosis based on curve size and skeletal maturity
Purpose To define the risk of curve progression of idiopathic scoliosis (IS) to 35°, 40°, 45°, and 50° based on current curve magnitude and Sanders stage for boys and girls, using a large cohort of patients and encounters, to improve granularity and allow more accurate estimations to guide treatment. Methods Retrospective analysis of a prospectively collected scoliosis database. Generalized estimation equation logistic regression models estimated probabilities of curve progression to 35°, 40°, 45°, and 50° based on starting curve size and Sanders stage. Probabilities and their 95% confidence intervals were calculated for each combination of variables to each endpoint separately for boys and girls. Results A total of 309 patients (80% girls) were included. Starting curve size and Sanders stage were significant predictors for progression in both sexes (all P ≤ 0.04). Higher starting curve sizes and lower Sanders stages were associated with greater odds of progression. Risk of progression was still present even at higher Sanders stages. Conclusion IS curves follow a predictable pattern, having more risk for progression when curves are larger and Sanders stages are smaller. Risk of curve progression is a spectrum based on these factors, indicating some risk of progression exists even for many smaller curves with higher Sanders stages. The improved granularity of this analysis compared to prior efforts may be useful for counseling patients about the risks of curve progression to various curve size endpoints and may aid shared decision-making regarding treatments. Level of evidence or clinical relevance Level III: retrospective cohort study.
- 12 August 2024
- Published by Springer Nature in Spine Deformity
- Vol. 12 (6) , 1657-1665
Improving prediction of progression of idiopathic scoliosis based on curve size and skeletal maturity
Purpose To define the risk of curve progression of idiopathic scoliosis (IS) to 35°, 40°, 45°, and 50° based on current curve magnitude and Sanders stage for boys and girls, using a large cohort of patients and encounters, to improve granularity and allow more accurate estimations to guide treatment. Methods Retrospective analysis of a prospectively collected scoliosis database. Generalized estimation equation logistic regression models estimated probabilities of curve progression to 35°, 40°, 45°, and 50° based on starting curve size and Sanders stage. Probabilities and their 95% confidence intervals were calculated for each combination of variables to each endpoint separately for boys and girls. Results A total of 309 patients (80% girls) were included. Starting curve size and Sanders stage were significant predictors for progression in both sexes (all P ≤ 0.04). Higher starting curve sizes and lower Sanders stages were associated with greater odds of progression. Risk of progression was still present even at higher Sanders stages. Conclusion IS curves follow a predictable pattern, having more risk for progression when curves are larger and Sanders stages are smaller. Risk of curve progression is a spectrum based on these factors, indicating some risk of progression exists even for many smaller curves with higher Sanders stages. The improved granularity of this analysis compared to prior efforts may be useful for counseling patients about the risks of curve progression to various curve size endpoints and may aid shared decision-making regarding treatments. Level of evidence or clinical relevance Level III: retrospective cohort study.
- 9 June 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107697
Association of antibiotics with the outcomes in COVID-19 pneumonia patients with elevated PCT levels
- 9 June 2024
- Published by Elsevier in Respiratory Medicine
- Vol. 231, 107697
Association of antibiotics with the outcomes in COVID-19 pneumonia patients with elevated PCT levels
- Open Access
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Depression is associated with dementia and accelerated cognitive decline in African Americans
Background: African Americans (AA) represent 12% of the United States population ≥65 years‐old, but 19% of persons with dementia. Inequalities in social determinants of health may influence access to healthcare resources contributing to increased dementia risk. Modifiable risk factors, including vascular risk factors and depression, may contribute up to 40% of dementia risk and are overrepresented in AA. Accordingly, risk factor modification in AA may improve disparities and decrease dementia risk.Method: Dementia risk factors were evaluated in community‐dwelling AA (n = 261) and non‐Hispanic White (NHW; n = 193) participants who completed ≥2 research visits in studies of memory and aging at the Mayo Clinic Florida Alzheimer Disease Research Center. The association between modifiable risk factors and cognitive impairment (global Clinical Dementia Rating® [CDR] ≥0.5), and rates of decline in impaired participants (measured using the CDR Sum‐of‐Boxes; CDR‐sb) were compared between AA and NHW, while controlling for demographics, APOEe4 status, and Area Deprivation Index.Result: Modifiable dementia risk factors were common in AA and NHW participants. The ADI was higher in AA denoting greater socioeconomic and environmental deprivation [7.8 (2.3) vs. 4.0 (2.1); p95% = 2.52, 1.08‐5.83) was associated with an increased odds of dementia in AA participants only, while depression was associated with an increased odds of dementia in both AA (3.10, 1.52‐6.30) and NHW (3.46, 1.14‐10.48) participants. Moreover, depression (β, CI95% = 1.55, 0.5‐2.6), p = 0.004) was associated with a faster rate of decline (CDR‐sb) in cognitively impaired AA participants. AA participants with depression were disproportionately less likely to report use of antidepressant medications than NHW counterparts (40/45, 89% vs. 21/44, 48%); p<0.001).Conclusion: Modifiable risk factors associated with dementia were common in AA and NHW participants. Depression was associated with dementia in both AA and NHW but uniquely associated with an accelerated rate of cognitive decline in AA participants. Disparities in use of antidepressant medications may contribute to these differences. Optimizing depression treatment in AA communities may improve cognitive trajectories and dementia risk in this population.
- 25 December 2023
- Published by Wiley in Alzheimer's & Dementia
- Vol. 19 (S18)
Open AccessDepression is associated with dementia and accelerated cognitive decline in African Americans
Background: African Americans (AA) represent 12% of the United States population ≥65 years‐old, but 19% of persons with dementia. Inequalities in social determinants of health may influence access to healthcare resources contributing to increased dementia risk. Modifiable risk factors, including vascular risk factors and depression, may contribute up to 40% of dementia risk and are overrepresented in AA. Accordingly, risk factor modification in AA may improve disparities and decrease dementia risk.Method: Dementia risk factors were evaluated in community‐dwelling AA (n = 261) and non‐Hispanic White (NHW; n = 193) participants who completed ≥2 research visits in studies of memory and aging at the Mayo Clinic Florida Alzheimer Disease Research Center. The association between modifiable risk factors and cognitive impairment (global Clinical Dementia Rating® [CDR] ≥0.5), and rates of decline in impaired participants (measured using the CDR Sum‐of‐Boxes; CDR‐sb) were compared between AA and NHW, while controlling for demographics, APOEe4 status, and Area Deprivation Index.Result: Modifiable dementia risk factors were common in AA and NHW participants. The ADI was higher in AA denoting greater socioeconomic and environmental deprivation [7.8 (2.3) vs. 4.0 (2.1); p95% = 2.52, 1.08‐5.83) was associated with an increased odds of dementia in AA participants only, while depression was associated with an increased odds of dementia in both AA (3.10, 1.52‐6.30) and NHW (3.46, 1.14‐10.48) participants. Moreover, depression (β, CI95% = 1.55, 0.5‐2.6), p = 0.004) was associated with a faster rate of decline (CDR‐sb) in cognitively impaired AA participants. AA participants with depression were disproportionately less likely to report use of antidepressant medications than NHW counterparts (40/45, 89% vs. 21/44, 48%); p<0.001).Conclusion: Modifiable risk factors associated with dementia were common in AA and NHW participants. Depression was associated with dementia in both AA and NHW but uniquely associated with an accelerated rate of cognitive decline in AA participants. Disparities in use of antidepressant medications may contribute to these differences. Optimizing depression treatment in AA communities may improve cognitive trajectories and dementia risk in this population.
- Open Access
- 4 December 2023
- Published by Elsevier in CHEST Critical Care
- Vol. 2 (1)
Procalcitonin Levels and Bacterial Coinfection in Hospitalized Patients With COVID-19
- 4 December 2023
- Published by Elsevier in CHEST Critical Care
- Vol. 2 (1)
Open AccessProcalcitonin Levels and Bacterial Coinfection in Hospitalized Patients With COVID-19
- 16 November 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (2) , 211-216
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.
- 16 November 2023
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 59 (2) , 211-216
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy
Outcomes are poor for patients with relapsed and/or refractory (R/R) large B-cell lymphoma (LBCL) post chimeric antigen receptor T-cell (CAR-T) therapy. Two CD19-directed therapies, tafasitamab- cxix plus lenalidomide (tafa-len) and loncastuximab tesirine (loncaT) are approved in R/R LBCL. The efficacy of these CD19 directed therapies in patients who relapse after CD19 directed CAR-T (CD19-CART) therapy is not well understood. We conducted a multi-center study of patients with R/R LBCL that received either tafa-len or loncaT at any timepoint for R/R disease after CD19-CART therapy. Fifty-three patients were included in this study with the median follow up of 56 (9.1–199) weeks from CAR-T infusion. Median number of systemic therapies pre–CAR-T therapy was 3 (range: 1–6); axicabtagene ciloleucel was the most utilized CAR-T product (n = 32,60%). Median time from CAR-T therapy to tafa-len or loncaT was 7.3 (1.2–38.2) months with median number of lines of therapy between CAR-T therapy and these regimens of 1 (0–5). Combined overall response rate and complete response rates were 27% and 10%, respectively. Median duration of response was 13.3 (2.1–56.7) weeks. In this real-world study, the use of currently approved CD19-directed therapies to treat R/R LBCL after CD19-CAR-T therapy showed limited clinical activity and duration of responses.